| Lightcalls.com |
|
|
![]() |
Choosing cruelty-free beauty produc...Choosing cruelty-free beauty products Based in succession historical record, it's a foregone conclusion that other species have been exploited to "better" mankind. As early as the third centenary B.C., Erasistratus of Alexandria recorded the mutilation of live animals to research the body humors. Galen sundered the nerves of live pigs and recorded the predictable be the effects Descartes, the 16th century French philosopher, maintained that animals were incapable of emotional rejoinder of feeling distress or pain. Unfortunately, this combination of parts to form a whole of belief dominated public perceptions well into the 18th century From science lab to menagerie In the cosmetic industry, it may flow as a surprise to many that manufacturers are not required to specifically use animals to trial the safety of their issues In fact, cosmetic manufacturers are not required to safety trial their products at all prior to pre-market approval. However, the forage and Drug Administration (FDA) does drive manufacturers to substantiate the safety of a particular cosmetic produce in order to protect human health. Of course, the simple phrase "Warning -- the safety of this production has not been determined" appearing forward the label releases manufacturers from regulatory persecution. greatest in quantity manufacturers wish to convey an image of accountability to the two consumers and the FDA, however, and one continue to use animals in order to try it. Rats and mice comprise about 85 to 90 percent of all animals used in testing and research laboratories. Rabbits, guinea pigs and hamsters come next with non-human primates, dogs and cats making up approximately the same percent. An estimated 27 percent of all animal experiments--especially in the case of the latter dispose of subjects -- are used to further medical research. The remaining 73 percent are mannersed to promote consumer product testing and education. Prior to the early 1980 nearly all cosmetic proceedss were tested on live animals. While whole-animal testing in the cosmetic industry has newly been reduced by nearly 90 percent there are still a companies that continue to use live animals to establish the safety of their fruitss There are two main reasons for this: to chop costs, and the lack of regulatory acceptance of alternative [i]modus operandi[/i]s of testing. Nevertheless, the National Institutes of Health (NIH) Revitalization Act of 1993 activeed the later creation of the Interagency Coordinating Committee upon the Validation of Alternative rules (ICCVAM), in 1997. According to its mission, ICCVAM must "facilitate communication among all stakeholders in the increase and review process of alternative" toxicity testing. This has changed the complexion of cosmetic safety testing, for the time being anyway. ICCVAM unites representatives from 14 federal agencies, including the FDA, and helps them validate and coordinate toxicological criterion methods. ICCVAM is also responsible for the growth and validation of alternative trial methods that protect both humans and animals, enabling these agencies to make informed regulatory decisions. However, at existing ICCVAM remains an ad hoc committee and, until it is given permanent status, there is no guarantee that humane testing techniques will be further explored and upheld. The 3 "Rs" of Reform ICCVAM defines an acceptable alternative testing process as any model capable of achieving "replacement, reduction, or refinement." Reduction in the number of animals used, or refinement of a ordeal to inflict less pain and stres onward any animal is a positive degree But, replacement of an animal bring under rule is, obviously, the ideal goal. There are 13 standard originals of safety o tests routinely deportment ed on a cosmetic product geared to evaluate the potential for watch irritation, oral acute toxicity, photosensitivity and skin irritation. The public is principally familiar with the more archaic and brutal of these criterions -- the Draize and LD50 touchstones that cruelly blind animals and kill half of the ordeal group, respectively. But, thanks to ICCVAM, and other progressive agencies, these experiments are beginning to fall to the wayside in favor of les invasive and thorough non-animal alternatives. Here's a rundown of the kinds of alternative touchstone models peering over the horizon: Caenorhabditis elegans - This small multi-celled organism is used to decrease the number of many animals used in experiments to determine toxicity. C elegans is the and nothing else multi-cellular organism in which scientists have documented each cell division occurring from a single fertilized harry to a mature 959-cell adult. newly tests have revealed that toxicity testing with C elegans is comparable to previous animal studies and has shown reliability in screening potentially toxic compounds Cultur human skin - The Neutral R and Alamar livid Bioassays use human skin small rooms to assess the absorption rate of water-soluble shade as an indicator of skin toxicity. Testskin is a fruit that measures relative toxicity and is actually human skin grown in sterile plastic bags. |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |